Universal Ibogaine Inc. Stock

Equities

IBO

CA91360F1099

Healthcare Facilities & Services

Market Closed - Toronto S.E. 10:07:00 2024-04-26 am EDT 5-day change 1st Jan Change
0.015 CAD 0.00% Intraday chart for Universal Ibogaine Inc. 0.00% +200.00%
Sales 2022 1.07 1.46 Sales 2023 1.03 1.41 Capitalization 2.87M 3.93M
Net income 2022 -10M -13.67M Net income 2023 -2M -2.73M EV / Sales 2022 8,069,982 x
Net Debt 2022 1.01M 1.38M Net Debt 2023 2.46M 3.37M EV / Sales 2023 5,181,017 x
P/E ratio 2022
-0.67 x
P/E ratio 2023
-1.2 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Current month-40.00%
1 month-40.00%
3 months+50.00%
6 months+50.00%
Current year+200.00%
More quotes
1 week
0.02
Extreme 0.015
0.02
1 month
0.02
Extreme 0.015
0.03
Current year
0.01
Extreme 0.005
0.03
1 year
0.01
Extreme 0.005
0.03
3 years
0.01
Extreme 0.005
0.25
5 years
0.01
Extreme 0.005
0.25
10 years
0.01
Extreme 0.005
0.25
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-01-09
Director of Finance/CFO 59 -
Chief Operating Officer - -
Members of the board TitleAgeSince
Chief Executive Officer - 22-01-09
Director/Board Member - 23-09-30
More insiders
Date Price Change Volume
24-04-26 0.015 0.00% 94,000
24-04-25 0.015 0.00% 2,060
24-04-24 0.015 0.00% 39,005
24-04-23 0.015 -25.00% 155,000
24-04-22 0.02 +33.33% 2,001

Delayed Quote Toronto S.E., April 26, 2024 at 10:07 am EDT

More quotes
Universal Ibogaine Inc. is a Canada-based life sciences company. The Company is focused on developing a network of addiction treatment clinics and undertake a planned clinical trial for research into the use of ibogaine for addiction treatment. Ibogaine is a naturally-occurring molecule derived from the root bark of the iboga tree and other plants. Ibogaine is a neuroactive compound that appears to reset the brains of drug dependent individuals to a pre-addicted state. Ibogaine has demonstrated effectiveness in treating opioid use disorder and it appears to eliminate the painful symptoms of opioid withdrawal and provides a several month window free of drug cravings. Ibogaine targets multiple receptor sites in the brain when it manages dopamine and serotonin circuits and stimulates new brain cell growth.
More about the company